• Türkçe
    • English
  • Türkçe 
    • Türkçe
    • English
  • Giriş
Öğe Göster 
  •   RTEÜ
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
  • WoS İndeksli Yayınlar Koleksiyonu
  • Öğe Göster
  •   RTEÜ
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
  • WoS İndeksli Yayınlar Koleksiyonu
  • Öğe Göster
JavaScript is disabled for your browser. Some features of this site may not work without it.

Rivaroxaban for thromboprophylaxis after hospitalization for medical illness

Thumbnail

Göster/Aç

Full Text / Tam Metin (368.8Kb)

Erişim

info:eu-repo/semantics/closedAccess

Tarih

2018

Yazar

Spyropoulos, Alex C.
Ageno, Walter
Albers, Gregory W.
Elliott, C. Gregory
Halperin, Jonathan L.
Hiatt, William R.
Kaatz, Scott

Üst veri

Tüm öğe kaydını göster

Künye

Spyropoulos, A. C., Ageno, W., Albers, G. W., Elliott, C. G., Halperin, J. L., Hiatt, W. R., Maynard, G. A., Steg, P. G., Weitz, J. I., Suh, E., Spiro, T. E., Barnathan, E. S., Raskob, G. E., & MARINER Investigators (2018). Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. The New England journal of medicine, 379(12), 1118–1127. https://doi.org/10.1056/NEJMoa1805090

Özet

BACKGROUND Patients who are hospitalized for medical illness remain at risk for venous thromboembolism after discharge, but the role of extended thromboprophylaxis in the treatment of such patients is a subject of controversy. METHODS in this randomized, double-blind trial, medically ill patients who were at increased risk for venous thromboembolism on the basis of a modified International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) score of 4 or higher (scores range from 0 to 10, with higher scores indicating a higher risk of venous thromboembolism) or a score of 2 or 3 plus a plasma n-dimer level of more than twice the upper limit of the normal range (defined according to local laboratory criteria) were assigned at hospital discharge to either once-daily rivaroxaban at a dose of 10 mg (with the dose adjusted for renal insufficiency) or placebo for 45 days. the primary efficacy outcome was a composite of symptomatic venous thromboembolism or death due to venous thromboembolism. the principal safety outcome was major bleeding. RESULTS of the 12,024 patients who underwent randomization, 12,019 were included in the intention-to-treat analysis. the primary efficacy outcome occurred in 50 of 6007 patients (0.83%) who were given rivaroxaban and in 66 of 6012 patients (1.10%) who were given placebo (hazard ratio, 0.76; 95% confidence interval [CI], 0.52 to 1.09; P=0.14). the prespecified secondary outcome of symptomatic nonfatal venous thromboembolism occurred in 0.18% of patients in the rivaroxaban group and 0.42% of patients in the placebo group (hazard ratio, 0.44; 95% CI, 0.22 to 0.89). Major bleeding occurred in 17 of 5982 patients (0.28%) in the rivaroxaban group and in 9 of 5980 patients (0.15%) in the placebo group (hazard ratio, 1.88; 95% CI, 0.84 to 4.23). CONCLUSIONS Rivaroxaban, given to medical patients for 45 days after hospital discharge, was not associated with a significantly lower risk of symptomatic venous thromboembolism and death due to venous thromboembolism than placebo. the incidence of major bleeding was low.

Kaynak

New England Journal of Medicine

Cilt

379

Sayı

12

Bağlantı

https://doi.org/10.1056/NEJMoa1805090
https://hdl.handle.net/11436/1759

Koleksiyonlar

  • PubMed İndeksli Yayınlar Koleksiyonu [2443]
  • TF, Dahili Tıp Bilimleri Bölümü Koleksiyonu [1559]
  • WoS İndeksli Yayınlar Koleksiyonu [5260]



DSpace software copyright © 2002-2015  DuraSpace
İletişim | Geri Bildirim
Theme by 
@mire NV
 

 




| Yönerge | Rehber | İletişim |

DSpace@RTEÜ

by OpenAIRE
Gelişmiş Arama

sherpa/romeo

Göz at

Tüm DSpaceBölümler & KoleksiyonlarTarihe GöreYazara GöreBaşlığa GöreKonuya GöreTüre GöreDile GöreBölüme GöreKategoriye GöreYayıncıya GöreErişim ŞekliKurum Yazarına GöreBu KoleksiyonTarihe GöreYazara GöreBaşlığa GöreKonuya GöreTüre GöreDile GöreBölüme GöreKategoriye GöreYayıncıya GöreErişim ŞekliKurum Yazarına Göre

Hesabım

GirişKayıt

İstatistikler

Google Analitik İstatistiklerini Görüntüle

DSpace software copyright © 2002-2015  DuraSpace
İletişim | Geri Bildirim
Theme by 
@mire NV
 

 


|| Rehber|| Yönerge || Kütüphane || Recep Tayyip Erdoğan Üniversitesi || OAI-PMH ||

Recep Tayyip Erdoğan Üniversitesi, Rize, Türkiye
İçerikte herhangi bir hata görürseniz, lütfen bildiriniz:

Creative Commons License
Recep Tayyip Erdoğan Üniversitesi Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace@RTEÜ:


DSpace 6.2

tarafından İdeal DSpace hizmetleri çerçevesinde özelleştirilerek kurulmuştur.